EA
AVBP icon

Ellsworth Advisors’s ArriVent BioPharma AVBP Stock Holding History

Ellsworth Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$890K Buy
+27,001
New +$797K 0.15% 124

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ellsworth Advisors's AVBP Position: Q2 2026 in Review

Ellsworth Advisors opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 27,001 shares worth $890K. The stake represents 0.15% of the portfolio and ranks #124 among its holdings.

157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Ellsworth Advisors held 27,001 shares of ArriVent BioPharma worth $890K as of Q2 2026.
  • ArriVent BioPharma was a new Ellsworth Advisors position in Q2 2026.
  • ArriVent BioPharma made up 0.15% of Ellsworth Advisors's portfolio in Q2 2026, its #124 holding.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Ellsworth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.